Factors Associated with Survival From Xp11.2 Translocation Renal Cell Carcinoma Diagnosis—A Systematic Review and Pooled Analysis

Purpose: Xp11.2 translocation renal cell carcinoma (Xp11.2 tRCC) is a rare subtype of renal cell carcinoma (RCC), characterized by translocations of Xp11.2 breakpoints, involving of the transcription factor three gene (TFE3). The aim of our study was to comprehensively characterize the clinical characteristics and outcomes, and to identify risk factors associated with OS and PFS in Xp11.2 tRCC patients.Methods: Literature search on Xp11.2 tRCC was performed using databases such as pubmed EMBASE and Web of Science. Studies were eligible if outcomes data (OS and/or PFS) were reported for patients with a histopathologically confirmed Xp11.2 tRCC. PFS and OS were evaluated using the univariable and multivariable Cox regression model.Results: There were 80 eligible publications, contributing 415 patients. In multivariable analyses, the T stage at presentation was significantly associated with PFS (HR: 3.87; 95% CI: 1.70 to 8.84; p = 0.001). The median time of PFS was 72 months. In the multivariable analyses, age at diagnosis (HR: 2.16; 95% CI: 1.03 to 4.50; p = 0.041), T stage at presentation (HR: 4.44; 95% CI: 2.16 to 9.09; p < 0.001) and metastasis status at presentation (HR: 2.67; 95% CI: 1.12 to 6.41; p = 0.027) were all associated with OS, with a median follow-up time of 198 months.Conclusion: T stage at presentation is the only factor that is associated with both PFS and OS in patients with Xp11.2 tRCC. Also, patients over 45 or with metastases are more likely to have poorer OS.

Download Full-text

Preoperative Plasma Fibrinogen: An Independent Predictor for Survival in Adult Patients with Xp11.2 Translocation Renal Cell Carcinoma

10.21203/rs.3.rs-67614/v1 ◽

2020 ◽

Author(s):

Jie Dong ◽

Weifeng Xu ◽

Zhigang Ji ◽

Boju Pan

Keyword(s):

Risk Factors ◽

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Distant Metastasis ◽

Renal Cell ◽

Cox Regression ◽

Progression Free Survival ◽

Adult Patients ◽

Plasma Fibrinogen ◽

Xp11.2 Translocation

Abstract Background. Xp11.2 translocation renal cell carcinoma, a rare malignancy, is more common in children than in adults. It manifests with an aggressive course in adults and relatively indolent in children. Prognostic studies for adult patients are scare for the rarity of the disease; and the prognostic value of preoperative plasma fibrinogen awaits further illumination.Methods. This retrospective single-center study enrolled 24 consecutive newly diagnosed Xp11.2 translocation RCC adult patients. Clinical presentations, baseline laboratory results and follow-up data were collected. Possible risk factors for progression free survival and overall survival were first scanned with chi-square tests and t-tests to compare patients who suffered from progression or death and who did not. Multivariate Cox regression was further utilized to identify independent risk factors.Results. Twenty-four adult patients (median age 32, range 16-73), with a male-to-female ratio of 1:1, was included from 2010.4 to 2020.3. After a mean follow-up of 35.7months, seven patients died. With univariate analysis, higher C-reactive protein-to-albumin ratio (p=0.028), higher baseline fibrinogen (p=0.006), and presence of distant metastasis (p=0.007) were associated with progression of disease; higher preoperative fibrinogen (p=0.014) and distant metastasis (p=0.020) were associated with death. With multivariate Cox regression, only baseline fibrinogen level (p=0.001) was identified as an independent risk factor for progression free survival; meanwhile, fibrinogen level (p=0.048) and distant metastasis (p=0.043) were identified as independent risk factors for survival.Conclusions. Preoperative plasma fibrinogen, a routinely tested parameter before surgery, is a promising tool for risk stratification in adult patients with Xp11.2 translocation renal cell carcinoma.JIE et al: Preoperative plasma fibrinogen predicts outcome in Xp11.2 translocation RCC

Download Full-text

Predictive value of De Ritis ratio in metastatic renal cell carcinoma treated with tyrosine-kinase inhibitors

World Journal of Urology ◽

10.1007/s00345-021-03628-2 ◽

2021 ◽

Author(s):

Florian Janisch ◽

Thomas Klotzbücher ◽

Phillip Marks ◽

Christina Kienapfel ◽

Christian P. Meyer ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Tyrosine Kinase ◽

Cell Carcinoma ◽

Tyrosine Kinase Inhibitors ◽

Metastatic Renal Cell Carcinoma ◽

Renal Cell ◽

Kinase Inhibitors ◽

Cox Regression ◽

Clear Cell ◽

Multivariable Analyses

Abstract Background Predictive markers can help tailor treatment to the individual in metastatic renal cell carcinoma (mRCC). De Ritis ratio (DRR) is associated with oncologic outcomes in various solid tumors. Objective To assess the value of DRR in prognosticating survival in mRCC patients treated with tyrosine-kinase inhibitors (TKI). Methods Overall, 220 mRCC patients treated with TKI first-line therapy were analyzed. An optimal cut-off point for DRR was determined with Youden’s J. We used multiple strata for DRR, performed descriptive, Kaplan–Meier and multivariable Cox-regression analyses to assess associations of DRR with progression-free (PFS) and overall survival (OS). Results Patients above the optimal cut-off point for DRR of ≥ 1.58 had fewer liver metastases (p = 0.01). There was no difference in PFS (p > 0.05) between DRR groups. DRR above the median of 1.08 (HR 1.42; p = 0.03), DRR ≥ 1.1(HR 1.44; p = 0.02), ≥ 1.8 (HR 1.56; p = 0.03), ≥ 1.9 (HR 1.59; p = 0.02) and ≥ 2.0 (HR 1.63; p = 0.047) were associated with worse OS. These associations did not remain after multivariable adjustment. In the intermediate MSKCC group, DRR was associated with inferior OS at cut-offs ≥ 1.0 (HR 1.78; p = 0.02), ≥ 1.1 (HR 1.81; p = 0.01) and above median (HR 1.88; p = 0.007) in multivariable analyses. In patients with clear-cell histology, DRR above median (HR 1.54; p = 0.029) and DRR ≥ 1.1 (HR 1.53; p = 0.029) were associated with OS in multivariable analyses. Conclusion There was no independent association between DRR and survival of mRCC patients treated with TKI in the entire cohort. However, OS of patients with intermediate risk and clear-cell histology were affected by DRR. DRR could be used for tailored decision-making in these subgroups.

Download Full-text

Coffee consumption and risk of renal cell carcinoma in the NIH-AARP Diet and Health Study

International Journal of Epidemiology ◽

10.1093/ije/dyab011 ◽

2021 ◽

Author(s):

Jongeun Rhee ◽

Erikka Loftfield ◽

Neal D Freedman ◽

Linda M Liao ◽

Rashmi Sinha ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Cox Regression ◽

Coffee Consumption ◽

Health Study ◽

Coffee Intake ◽

Decaffeinated Coffee ◽

Incident Cases ◽

Reduced Risk

Abstract Background Coffee consumption has been associated with a reduced risk of some cancers, but the evidence for renal cell carcinoma (RCC) is inconclusive. We investigated the relationship between coffee and RCC within a large cohort. Methods Coffee intake was assessed at baseline in the National Institutes of Health–American Association of Retired Persons Diet and Health Study. Among 420 118 participants eligible for analysis, 2674 incident cases were identified. We fitted Cox-regression models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for coffee consumption vs non-drinkers. Results We observed HRs of 0.94 (95% CI 0.81, 1.09), 0.94 (0.81, 1.09), 0.80 (0.70, 0.92) and 0.77 (0.66, 0.90) for usual coffee intake of <1, 1, 2–3 and ≥4 cups/day, respectively (Ptrend = 0.00003). This relationship was observed among never-smokers (≥4 cups/day: HR 0.62, 95% CI 0.46, 0.83; Ptrend = 0.000003) but not ever-smokers (HR 0.85, 95% CI 0.70, 1.05; Ptrend = 0.35; Pinteraction = 0.0009) and remained in analyses restricted to cases diagnosed >10 years after baseline (HR 0.65, 95% CI 0.51, 0.82; Ptrend = 0.0005). Associations were similar between subgroups who drank predominately caffeinated or decaffeinated coffee (Pinteraction = 0.74). Conclusion In this investigation of coffee and RCC, to our knowledge the largest to date, we observed a 20% reduced risk for intake of ≥2 cups/day vs not drinking. Our findings add RCC to the growing list of cancers for which coffee consumption may be protective.

Download Full-text

Renal cell carcinoma associated with Xp11.2 translocation/TFE gene fusion: imaging findings in 21 patients

European Radiology ◽

10.1007/s00330-016-4421-4 ◽

2016 ◽

Vol 27 (2) ◽

pp. 543-552 ◽

Cited By ~ 7

Author(s):

Xiao Chen ◽

Qingqiang Zhu ◽

Baoxin Li ◽

Wenjing Cui ◽

Hao Zhou ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Gene Fusion ◽

Fusion Imaging ◽

Imaging Findings ◽

Xp11.2 Translocation

Download Full-text

PD-L1 expression is associated with tumor progression and poor prognosis in Xp11.2 translocation renal cell carcinoma

European Urology Supplements ◽

10.1016/s1569-9056(18)30861-3 ◽

2018 ◽

Vol 17 (2) ◽

pp. e13

Author(s):

Z. Yiping ◽

Y.-Y. Qu ◽

K. Chang ◽

W.-J. Xaio ◽

H.-K. Wang ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Tumor Progression ◽

Cell Carcinoma ◽

Renal Cell ◽

Poor Prognosis ◽

Xp11.2 Translocation

Download Full-text

Renal cell carcinoma in children and young adults: analysis of clinicopathological, immunohistochemical and molecular characteristics with an emphasis on the spectrum of Xp11.2 translocation-associated and unusual clear cell subtypes

Histopathology ◽

10.1111/j.1365-2559.2008.03151.x ◽

2008 ◽

Vol 53 (5) ◽

pp. 533-544 ◽

Cited By ~ 62

Author(s):

A Wu ◽

L P Kunju ◽

L Cheng ◽

R B Shah

Keyword(s):

Renal Cell Carcinoma ◽

Young Adults ◽

Cell Carcinoma ◽

Renal Cell ◽

Clear Cell ◽

Molecular Characteristics ◽

Children And Young Adults ◽

Xp11.2 Translocation

Download Full-text

Xp11.2 translocation renal cell carcinoma with egg-shell calcification mimicking a benign renal tumour: A case report

Oncology Letters ◽

10.3892/ol.2015.3718 ◽

2015 ◽

Vol 10 (5) ◽

pp. 3191-3194 ◽

Cited By ~ 1

Author(s):

WENJIE LIANG ◽

SHUNLIANG XU

Keyword(s):

Renal Cell Carcinoma ◽

Case Report ◽

Cell Carcinoma ◽

Renal Cell ◽

Renal Tumour ◽

Xp11.2 Translocation ◽

Egg Shell

Download Full-text

Factors associated with palliative intervention utilization for metastatic renal cell carcinoma

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2022.01.001 ◽

2022 ◽

Author(s):

Hiren V. Patel ◽

Sinae Kim ◽

Arnav Srivastava ◽

Brian M. Shinder ◽

Joshua Sterling ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Renal Cell ◽

Factors Associated

Download Full-text

Adult Xp11.2 translocation renal cell carcinoma managed effectively with pazopanib

BMJ Case Reports ◽

10.1136/bcr-2021-243058 ◽

2021 ◽

Vol 14 (6) ◽

pp. e243058

Author(s):

Cristian Solano ◽

Shrinjaya Thapa ◽

Mohammad Muhsin Chisti

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Stable Disease ◽

Renal Cell ◽

Systemic Treatment ◽

Pulmonary Nodules ◽

Progression Of Disease ◽

Xp11.2 Translocation ◽

Adrenal Nodule

Xp11.2 translocation renal cell carcinoma (TRCC) is a rare and aggressive variant of renal cell carcinoma (RCC) when presenting in adults. We report a case of a man in his early 40s who was diagnosed with stage III Xp11.2 TRCC and underwent radical nephrectomy. Seven months following the surgery, an adrenal nodule and bilateral pulmonary nodules were discovered. He underwent cryoablation of the adrenal nodule and systemic treatment with daily pazopanib. He displayed stable disease for approximately 6 years. Following this period, multiple hospitalisations interrupted daily pazopanib therapy resulting in progression of disease. His regimen was then changed to ipilimumab and nivolumab, followed by current daily therapy with axitinib. The patient now shows stable disease in his 10th year after diagnosis. This case study demonstrates the efficacy of pazopanib for metastatic Xp11.2 TRCC and warrants further investigation to supplement the guidelines regarding the use of targeted therapy for TRCC.

Download Full-text